LCT: The cell implant company

Living Cell Technologies Limited (LCT) is a global pioneer in the field of cell encapsulation and implantation for human therapeutics.

LCT LCT LCT LCT
LCT is the first company globally to enter clinical trials using therapeutic porcine cell implants. DIABECELL® is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia. Tiny DIABECELL microspheres containing live islet cells are implanted into a patient's abdomen using a simple laparoscopic procedure. Once implanted, DIABECELL works by self-regulating and efficiently secreting insulin and glucagon in response to the patient's changing glucose levels. DIABECELL islets are protected from the body's immune response by LCT's breakthrough proprietary encapsulation technology, so DIABECELL patients do not require any immunosuppression.

Having completed a successful Phase I/IIa clinical trial in Russia, LCT currently has Phase IIb clinical trials underway in New Zealand and Argentina. Safety and preliminary efficacy data generated to date show promise that DIABECELL will change the paradigm for treating diabetes when it becomes the world's first approved porcine cell implant.

On 1 November 2011 LCT and Otsuka Pharmaceutical Factory, Inc. created a new company Diatranz Otsuka Limited (DOL) with cash of $A25,000,000 to accelerate the development and commercialisation of DIABECELL.

Using breakthrough proprietary micro-encapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss.
Register for email updates > View video